SEOM clinical guidelines for anaplastic gliomas (2017) (vol 20, pg 16, 2018)

被引：3

作者：

Balana, C. ^{[1
]}

Alonso, M. ^{[2
]}

Hernandez-Lain, A. ^{[3
]}

Perez-Segura, P. ^{[4
]}

Pineda, E. ^{[5
]}

Ramos, A. ^{[3
]}

Sanchez, A. R. ^{[6
]}

Teixidor, P. ^{[7
]}

Verger, E. ^{[5
]}

Benavides, M. ^{[8
]}

机构：

[1] Inst Catala Oncol Badalona, Ct Canyet S-N, Barcelona 08916, Spain

[2] Complejo Hosp Virgen del Rocio, Seville, Spain

[3] Hosp 12 Octubre, Madrid, Spain

[4] Hosp Univ Clin San Carlos, Madrid, Spain

[5] Hosp Clin Barcelona, Barcelona, Spain

[6] Complejo Asistencial Univ Leon, Leon, Spain

[7] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[8] Hosp Univ Reg & Virgen de la Victoria, Malaga, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2018年 / 20卷 / 07期

关键词：

D O I：

10.1007/s12094-018-1904-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnostic/prognostic and predictive value of IDH1/IDH2 missense mutations and 1p/19q codeletions in AG. The diagnosis of anaplastic oligoastrocytoma is discouraged. Surgery, radiotherapy and chemotherapy with PCV or TMZ are the first-line standard of care for AG with slight modifications according to molecular variables. A multidisciplinary team is highly recommended in the management of these tumors.

引用

页码：937 / 937

页数：1